PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227

H. Borghaei,J.R. Brahmer, J.-S. Lee,T.-E. Ciuleanu,R. Bernabe Caro,M. Nishio,L. Urban,C. Audigier-Valette,L. Lupinacci,R. Sangha,L.G. Paz-Ares,M. Reck,K. John O’Byrne,R.G. Gupta,J. Bushong,L. Li,S.I. Blum,L. Eccles,S.S. Ramalingam

Journal of thoracic oncology（2023）

引用 0|浏览19

暂无评分

摘要

In CheckMate 227 part 1 (NCT02477826), first-line NIVO+IPI demonstrated long-term, durable overall survival (OS) benefit versus chemotherapy (chemo) in patients with metastatic NSCLC (mNSCLC). Here we present 5-year outcomes (previous presentation: Brahmer ASCO2022 #LBA9025).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要